Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

Equities researchers at William Blair issued their Q1 2025 EPS estimates for Brilliant Earth Group in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst D ...

Fintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...

Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...